<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Oncología molecular > DA - CIMA - Oncología - Oncología molecular - Artículos de Revista >

LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome
Authors: Malumbres, R. (Raquel)
Fresquet, V. (Vicente)
Roman-Gomez, J. (José)
Bobadilla, M. (Míriam)
Robles, E.F. (Eloy Francisco)
Altobelli, G.G. (Giovanna G.)
Calasanz-Abinzano, M.J. (Maria Jose)
Smeland, E.B. (Erlend B.)
Aznar, M.A. (María Ángela)
Agirre, X. (Xabier)
Martin-Palanco, V. (Vanesa)
Prosper, F. (Felipe)
Lossos, I.S. (Izidore S.)
Martinez-Climent, J.A. (José Ángel)
Keywords: Acute leukemia
B lymphocytes
Gene expression
Prognostic factor
Issue Date: 2011
Publisher: Ferrata Storti Foundation
Publisher version:
ISSN: 1592-8721
Citation: Malumbres R, Fresquet V, Roman-Gomez J, Bobadilla M, Robles EF, Altobelli GG, et al. LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome. Haematologica 2011 Jul;96(7):980-986.
BACKGROUND: LMO2 is highly expressed at the most immature stages of lymphopoiesis. In T-lymphocytes, aberrant LMO2 expression beyond those stages leads to T-cell acute lymphoblastic leukemia, while in B cells LMO2 is also expressed in germinal center lymphocytes and diffuse large B-cell lymphomas, where it predicts better clinical outcome. The implication of LMO2 in B-cell acute lymphoblastic leukemia must still be explored. DESIGN AND METHODS: We measured LMO2 expression by real time RT-PCR in 247 acute lymphoblastic leukemia patient samples with cytogenetic data (144 of them also with survival and immunophenotypical data) and in normal hematopoietic and lymphoid cells. RESULTS: B-cell acute lymphoblastic leukemia cases expressed variable levels of LMO2 depending on immunophenotypical and cytogenetic features. Thus, the most immature subtype, pro-B cells, displayed three-fold higher LMO2 expression than pre-B cells, common-CD10+ or mature subtypes. Additionally, cases with TEL-AML1 or MLL rearrangements exhibited two-fold higher LMO2 expression compared to cases with BCR-ABL rearrangements or hyperdyploid karyotype. Clinically, high LMO2 expression correlated with better overall survival in adult patients (5-year survival rate 64.8% (42.5%-87.1%) vs. 25.8% (10.9%-40.7%), P= 0.001) and constituted a favorable independent prognostic factor in B-ALL with normal karyotype: 5-year survival rate 80.3% (66.4%-94.2%) vs. 63.0% (46.1%-79.9%) (P= 0.043). CONCLUSIONS: Our data indicate that LMO2 expression depends on the molecular features and the differentiation stage of B-cell acute lymphoblastic leukemia cells. Furthermore, assessment of LMO2 expression in adult patients with a normal karyotype, a group which lacks molecular prognostic factors, could be of clinical relevance.
Permanent link:
Appears in Collections:DA - Medicina - Hematología - Artículos de revista
DA - CUN - Hematología y Hemoterapia - Artículos de revista
DA - CIMA - Oncología - Oncología molecular - Artículos de Revista

Files in This Item:
File:  Haematol2011_96_7_980.pdf
Size:  511,32 kB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.